Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia (original) (raw)
Albus M, Ackenheil M, Engel RR, Muller F (1982) Situational reactivity of autonomic functions in schizophrenic patients. Psychiatry Res 6:361–370 ArticleCASPubMed Google Scholar
Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE (1997) Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 273:E425–E432 CASPubMed Google Scholar
Baron AD, Brechtel G, Johnson A, Fineberg N, Henry DP, Steinberg HO (1994) Interactions between insulin and norepinephrine on blood pressure and insulin sensitivity. Studies in lean and obese men. J Clin Invest 93:2453–2462 CASPubMed Google Scholar
Bird ED, Spokes EG, Iversen LL (1979a) Brain norepinephrine and dopamine in schizophrenia. Science 204:93–94 CASPubMed Google Scholar
Bird ED, Spokes EG, Iversen LL (1979b) Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain 102:347–360 CASPubMed Google Scholar
Breier A (1989) A.E. Bennett award paper. Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients. Biol Psychiatry 26:438–462 ArticleCASPubMed Google Scholar
Breier A, Wolkowitz OM, Roy A, Potter WZ, Pickar D (1990) Plasma norepinephrine in chronic schizophrenia. Am J Psychiatry 147:1467–1470 CASPubMed Google Scholar
Breier A, Davis O, Buchanan R, Listwak SJ, Holmes C, Pickar D, Goldstein DS (1992) Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. Biol Psychiatry 32:880–890 ArticleCASPubMed Google Scholar
Bridge TP, Kleinman JE, Karoum F, Wyatt RJ (1985) Postmortem central catecholamines and antemortem cognitive impairment in elderly schizophrenics and controls. Neuropsychobiology 14:57–61 CASPubMed Google Scholar
Brodows RG, Pi S, Campbell RG (1975) Sympathetic control of hepatic glycogenolysis during glucopenia in man. Metabolism 24:617–624 CASPubMed Google Scholar
Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701 ArticlePubMed Google Scholar
Chang PC, Krogt JA van der, Vermeij P, Brummelen P van (1986) Norepinephrine removal and release in the forearm of healthy subjects. Hypertension 8:801–809 CASPubMed Google Scholar
Crow TJ, Baker HF, Cross AJ, Joseph MH, Lofthouse R, Longden A, Owen F, Riley GJ, Glover V, Killpack WS (1979) Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings. Br J Psychiatry 134:249–256 CASPubMed Google Scholar
Davis SN, Cherrington AD, Goldstein RE, Jacobs J, Price L (1993a) Effects of insulin on the counterregulatory response to equivalent hypoglycemia in normal females. Am J Physiol 265:E680–E689 CASPubMed Google Scholar
Davis SN, Goldstein RE, Jacobs J, Price L, Wolfe R, Cherrington AD (1993b) The effects of differing insulin levels on the hormonal and metabolic response to equivalent hypoglycemia in normal humans. Diabetes 42:263–272 CASPubMed Google Scholar
Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903–912 CASPubMed Google Scholar
Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM, 3rd (2001) Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 13:103–113 ArticleCASPubMed Google Scholar
Egan MF, Hyde TM (2000) Schizophrenia: Neurobiology. In: Kaplan and Sadock (eds) Comprehensive textbook of psychiatry. Lippincott, Williams & Wilkins, Philadelphia
Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ (1986) Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32:2030–2033 CASPubMed Google Scholar
Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO, 3rd, Quyyumi AA, Lambert G, Chin J, Jennings GL, Goldstein DS (1992) Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 85:1775–1785 CASPubMed Google Scholar
Elman I, Goldstein DS, Eisenhofer G, Folio J, Malhotra AK, Adler CM, Pickar D, Breier A (1999a) Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology 20:29–34 ArticleCASPubMed Google Scholar
Elman I, Sokoloff L, Adler CM, Weisenfeld N, Breier A (1999b) The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers. Brain Res 815:243–249 ArticleCASPubMed Google Scholar
Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G (2001) Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 14:304S–309S ArticleCASPubMed Google Scholar
Farley IJ, Price KS, McCullough E, Deck JH, Hordynski W, Hornykiewicz O (1978) Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain. Science 200:456–458 CASPubMed Google Scholar
Finney GO (1989) Juvenile onset diabetes and schizophrenia? Lancet 2:1214–1215 ArticleCAS Google Scholar
Folkow B, Di Bona GF, Hjemdahl P, Toren PH, Wallin BG (1983) Measurements of plasma norepinephrine concentrations in human primary hypertension. A word of caution on their applicability for assessing neurogenic contributions. Hypertension 5:399–403 CASPubMed Google Scholar
Gagner JP, Gauthier S, Sourkes TL (1985) Descending spinal pathways mediating the responses of adrenal tyrosine hydroxylase and catecholamines to insulin and 2-deoxyglucose. Brain Res 325:187–197 ArticleCASPubMed Google Scholar
Gattaz WF, Riederer P, Reynolds GP, Gattaz D, Beckmann H (1983) Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 8:243–250 ArticleCASPubMed Google Scholar
Glazer WM, Charney DS, Heninger GR (1987) Noradrenergic function in schizophrenia. Arch Gen Psychiatry 44:898–904 CASPubMed Google Scholar
Goldstein D (1995) Stress, catecholamines, and cardiovascular disease. Oxford University, New York
Goldstein DS, Breier A, Wolkowitz OM, Pickar D, Lenders JW (1992) Plasma levels of catecholamines and corticotrophin during acute glucopenia induced by 2-deoxy-D-glucose in normal man. Clin Auton Res 2:359–366 CASPubMed Google Scholar
Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL (1999) Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 48:839–847 CASPubMed Google Scholar
Gotoh M, Takagi J, Mori S, Yatoh M, Hirooka Y, Yamanouchi K, Smythe GA (2001) Octreotide-induced suppression of the hyperglycemic response to neostigmine or bombesin: relationship to hypothalamic noradrenergic drive. Brain Res 919:155–159 ArticleCASPubMed Google Scholar
Havel PJ, Veith RC, Dunning BE, Taborsky GJ Jr (1988) Pancreatic noradrenergic nerves are activated by neuroglucopenia but not by hypotension or hypoxia in the dog. Evidence for stress-specific and regionally selective activation of the sympathetic nervous system. J Clin Invest 82:1538–1545 CASPubMed Google Scholar
Hevener AL, Bergman RN, Donovan CM (1997) Novel glucosensor for hypoglycemic detection localized to the portal vein. Diabetes 46:1521–1525 CASPubMed Google Scholar
Hevener AL, Bergman RN, Donovan CM (2000) Portal vein afferents are critical for the sympathoadrenal response to hypoglycemia. Diabetes 49:8–12 CASPubMed Google Scholar
Horton RW, Meldrum BS, Bachelard H (1973) Enzymic and cerebral metabolic effects of 2-deoxy-D-glucose. J Neurochem 21:507–520 Google Scholar
Kammen DP van, Peters J, Kammen WB van, Nugent A, Goetz KL, Yao J, Linnoila M (1989) CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry 26:176–188 ArticlePubMed Google Scholar
Kammen DP van, Peters J, Yao J, Kammen WB van, Neylan T, Shaw D, Linnoila M (1990) Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited. Arch Gen Psychiatry 47:161–168 PubMed Google Scholar
Kato MM, Goodnick PJ (2001) Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2:1571–1582 CASPubMed Google Scholar
Kemali D, Del Vecchio M, Maj M (1982) Increased noradrenaline levels in CSF and plasma of schizophrenic patients. Biol Psychiatry 17:711–717 CASPubMed Google Scholar
Kendler KS (1986) A twin study of mortality in schizophrenia and neurosis. Arch Gen Psychiatry 43:643–649 CASPubMed Google Scholar
Lake CR, Sternberg DE, Kammen DP van, Ballenger JC, Ziegler MG, Post RM, Kopin IJ, Bunney WE (1980) Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science 207:331–333 CASPubMed Google Scholar
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160:290–296 ArticlePubMed Google Scholar
Matsunaga H, Iguchi A, Yatomi A, Uemura K, Miura H, Gotoh M, Mano T, Sakamoto N (1989) The relative importance of nervous system and hormones to the 2-deoxy-D-glucose-induced hyperglycemia in fed rats. Endocrinology 124:1259–1264 CASPubMed Google Scholar
Mukherjee S, Roth SD, Sandyk R, Schnur DB (1989) Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Res 29:17–27 ArticleCASPubMed Google Scholar
Naber D, Finkbeiner C, Fischer B, Zander KJ, Ackenheil M (1980) Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms. Neuropsychobiology 6:181–189 CASPubMed Google Scholar
Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337–345 ArticleCASPubMed Google Scholar
Niijima A (1975) The effect of 2-deoxy-D-glucose and D-glucose on the efferent discharge rate of sympathetic nerves. J Physiol 251:231–243 CASPubMed Google Scholar
Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812 Google Scholar
Pascoe WS, Smythe GA, Storlien LH (1989) 2-deoxy-D-glucose-induced hyperglycemia: role for direct sympathetic nervous system activation of liver glucose output. Brain Res 505:23–28 ArticleCASPubMed Google Scholar
Popkin MK, Colon EA (2001) The interface of psychiatric disorders and diabetes mellitus. Curr Psychiatry Rep 3:243–250 CASPubMed Google Scholar
Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL (1998) Postmortem studies in schizophrenia. Schizophr Bull 24:325–341 CASPubMed Google Scholar
Riggs JE, Griggs RC, Moxley RT IIIrd (1984) Dissociation of glucose and potassium arterial-venous differences across the forearm by acetazolamide. A possible relationship to acetazolamide’s beneficial effect in hypokalemic periodic paralysis. Arch Neurol 41:35–38 CASPubMed Google Scholar
Ryan MC, Thakore JH (2002) Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71:239–257 ArticleCASPubMed Google Scholar
Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289 ArticlePubMed Google Scholar
Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004) The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 74:1999–2008 ArticleCASPubMed Google Scholar
Skyler JS (2000) Diabetes mellitus types I and II: classification and diagnosis. In: Humes HD (ed) Kelley’s textbook of internal medicine 4th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 2751–2752
Smythe GA, Edwards SR (1992) Suppression of central noradrenergic neuronal activity inhibits hyperglycemia. Am J Physiol 263:E823–E827 CASPubMed Google Scholar
Smythe GA, Grunstein HS, Bradshaw JE, Nicholson MV, Compton PJ (1984) Relationships between brain noradrenergic activity and blood glucose. Nature 308:65–67 CASPubMed Google Scholar
Smythe GA, Pascoe WS, Storlien LH (1989) Hypothalamic noradrenergic and sympathoadrenal control of glycemia after stress. Am J Physiol 256:E231–E235 CASPubMed Google Scholar
Stear S (2003) Health and fitness series. 1. The importance of physical activity for health. J Fam Health Care 13:10–13 PubMed Google Scholar
Stein L, Wise CD (1971) Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 171:1032–1036 CASPubMed Google Scholar
Sternberg DE, Kammen DP van, Lake CR, Ballenger JC, Marder SR, Bunney WE, Jr (1981) The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry 138:1045–1050 CASPubMed Google Scholar
Sternberg DE, Charney DS, Heninger GR, Leckman JF, Hafstad KM, Landis DH (1982) Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls. Arch Gen Psychiatry 39:285–289 CASPubMed Google Scholar
Storlien LH, Grunstein HS, Smythe GA (1985) Guanethidine blocks the 2-deoxy-D-glucose-induced hypothalamic noradrenergic drive to hyperglycemia. Brain Res 335:144–147 ArticleCASPubMed Google Scholar
Takahashi A, Ishimaru H, Ikarashi Y, Kishi E, Maruyama Y (1994) Hypothalamic cholinergic and noradrenergic neurons in hyperglycemia induced by 2-deoxyglucose. Brain Res 665:13–17 CASPubMed Google Scholar
Takahashi A, Ishimaru H, Ikarashi Y, Kishi E, Maruyama Y (1996) Hypothalamic cholinergic activity associated with 2-deoxyglucose-induced hyperglycemia. Brain Res 734:116–122 CASPubMed Google Scholar
Thibaut F, Ribeyre JM, Dourmap N, Menard JF, Dollfus S, Petit M (1998) Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Biol Psychiatry 43:24–30 Google Scholar
Tietz NW (1995) Clinical Guide to Laboratory Tests, 3rd edn. WA Saunders, Philadelphia
Walters JM, Ward GM, Barton J, Arackal R, Boston RC, Best JD, Alford FP (1997) The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes. Metabolism 46:1448–1453 CASPubMed Google Scholar
Wyngaarden JB, Smith LH (1988) Cecil Textbook of Medicine. Saunders Company, Philadelphia, pp 1381–1387
Yoshimatsu H, Oomura Y, Katafuchi T, Niijima A (1987) Effects of hypothalamic stimulation and lesion on adrenal nerve activity. Am J Physiol 253:R418–R424 CASPubMed Google Scholar